知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.014 秒)

    PHARMACEUTICAL COMPOSITIONS
    2.
    发明申请
    PHARMACEUTICAL COMPOSITIONS 审中-公开
    药物组合物

    公开(公告)号：US20090123543A1

    公开(公告)日：2009-05-14

    申请号：US12159506

    申请日：2007-01-02

    申请人： Pratibha S. Pilgaonkar ,  Maharukh T. Rustomjee ,  Anilkumar S. Gandhi ,  Paras R. Jain

    发明人： Pratibha S. Pilgaonkar ,  Maharukh T. Rustomjee ,  Anilkumar S. Gandhi ,  Paras R. Jain

    IPC分类号： A61K9/36 ,  A61K31/41 ,  A61K31/495 ,  A61P9/12 ,  A61K9/32 ,  A61K31/40

    CPC分类号： A61K9/2077 ,  A61K9/1617 ,  A61K9/1641 ,  A61K9/1682 ,  A61K9/2013 ,  A61K9/2031 ,  A61K9/2095

    摘要： A novel solid oral dosage form comprising a therapeutically effective amount of hydrophobic pharmacological active ingredient and at least one particle separating agent preferably selected from a class of wetting agents, prepared without or with minimum amount of a disintegrating agent. The hydrophobic pharmacological active ingredient active ingredient belongs to the class of angiotensin receptor blocking agents preferably is valsartan optionally in combination with hydrochlorothiazide. The active ingredient may also be a class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors preferably atorvastatin. The ratio of hydrophobic active ingredient to particle separating agent is about 20:1 to about 1:20. The process for the preparation of the novel solid oral dosage form comprises treating a hydrophobic active ingredient with at least one particle separating agent, and incorporating the treated hydrophobic active ingredient into a solid dosage form.

    摘要翻译： 一种新颖的固体口服剂型，其包含治疗有效量的疏水性药理学活性成分和至少一种优选选自一类润湿剂的颗粒分离剂，其不经或最少量的崩解剂制备。 疏水性药理活性成分活性成分属于血管紧张素受体阻断剂类别，优选缬沙坦，任选地与氢氯噻嗪组合。 活性成分也可以是优选阿托伐他汀的一类3-羟基-3-甲基戊二酰辅酶A（HMG CoA）还原酶抑制剂。 疏水活性成分与颗粒分离剂的比例为约20:1至约1:20。 用于制备新型固体口服剂型的方法包括用至少一种颗粒分离剂处理疏水性活性成分，并将经处理的疏水性活性成分掺入固体剂型中。

    Oral osmotic controlled drug delivery system for a sparingly soluble drug
    5.
    发明授权
    Oral osmotic controlled drug delivery system for a sparingly soluble drug 失效
    用于微溶药物的口服渗透控制药物递送系统

    公开(公告)号：US06534090B2

    公开(公告)日：2003-03-18

    申请号：US09891848

    申请日：2001-06-26

    申请人： Shivanand P. Puthli ,  Suma G. Menon ,  Jayant S. Karajgi ,  Nitin B. Dharmadhikari ,  Ratnesh H. Shrivastava ,  Pratibha S. Pilgaonkar

    发明人： Shivanand P. Puthli ,  Suma G. Menon ,  Jayant S. Karajgi ,  Nitin B. Dharmadhikari ,  Ratnesh H. Shrivastava ,  Pratibha S. Pilgaonkar

    IPC分类号： A61K924

    CPC分类号： A61K9/0004

    摘要： The present invention is for an oral osmotic controlled drug delivery system for a sparingly soluble drug comprising: a. a core comprising (i) finely particulate anhydrous carbamazepine (ii) a polymeric swelling agent consisting of one or more swellable hydrophilic polymers selected such that the polymeric swelling agent exhibits controlled swelling and the wall does not rupture or burst, (iii) a crystal habit modifier in whose presence, upon contact with an aqueous medium, the anhydrous carbamazepine being transformed into cuboidal or rod-shaped crystals of the dihydrate of carbamazepine, or mixtures thereof, and (iv) water-soluble compounds for inducing osmosis, b. a wall made of acylated cellulose which is impermeable to the components of the core, but permeable to water, and c. a passageway through the wall for releasing the components present in the core to the surrounding environment.

    摘要翻译： 本发明涉及用于微溶药物的口服渗透控制药物递送系统，其包括：a。 核心，其包含（i）细颗粒状无水卡马西平（ii）由一种或多种可溶胀亲水性聚合物组成的聚合物溶胀剂，其选择为使得聚合物溶胀剂显示可控膨胀并且壁不破裂或破裂，（iii）结晶习性 改性剂在与水性介质接触时，将无水卡马西平转化为卡马西平二水合物的立方或棒状晶体或其混合物，和（iv）用于诱导渗透的水溶性化合物，b。 由酰化纤维素制成的壁，其对芯的组分是不可渗透的，但是可渗透水，和c。 通过壁的通道，用于将存在于芯中的组分释放到周围环境。